These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 8774823)

  • 1. Electrophysiological findings in idiopathic recurrent ventricular fibrillation: special reference to mode of induction, drug testing, and long-term outcomes.
    Aizawa Y; Naitoh N; Washizuka T; Takahashi K; Uchiyama H; Shiba M; Shibata A
    Pacing Clin Electrophysiol; 1996 Jun; 19(6):929-39. PubMed ID: 8774823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Idiopathic ventricular fibrillation: clinical, electrophysiologic characteristics and long-term outcomes.
    Tsai CF; Chen SA; Tai CT; Chiang CE; Ding YA; Chang MS
    Int J Cardiol; 1998 Mar; 64(1):47-55. PubMed ID: 9579816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of ventricular fibrillation versus monomorphic ventricular tachycardia during programmed stimulation. Role of premature beat conduction delay.
    Avitall B; McKinnie J; Jazayeri M; Akhtar M; Anderson AJ; Tchou P
    Circulation; 1992 Apr; 85(4):1271-8. PubMed ID: 1372847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term reproducibility of electrophysiologically guided therapy with sotalol in patients with ventricular tachyarrhythmias.
    Mewis C; Kühlkamp V; Mermi J; Bosch RF; Seipel L
    J Am Coll Cardiol; 1999 Jun; 33(7):1989-95. PubMed ID: 10362204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of electrophysiologic-guided therapy with Class IA antiarrhythmic drugs on the long-term outcome of patients with idiopathic ventricular fibrillation with or without the Brugada syndrome.
    Belhassen B; Viskin S; Fish R; Glick A; Setbon I; Eldar M
    J Cardiovasc Electrophysiol; 1999 Oct; 10(10):1301-12. PubMed ID: 10515552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idiopathic ventricular fibrillation: inducibility and beneficial effects of class I antiarrhythmic agents.
    Belhassen B; Shapira I; Shoshani D; Paredes A; Miller H; Laniado S
    Circulation; 1987 Apr; 75(4):809-16. PubMed ID: 3829343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reappraisal of criteria for assessing drug efficacy in patients with ventricular tachyarrhythmias: complete versus partial suppression of inducible arrhythmias.
    Borggrefe M; Trampisch HJ; Breithardt G
    J Am Coll Cardiol; 1988 Jul; 12(1):140-9. PubMed ID: 3379199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term clinical outcome of ventricular tachycardia or fibrillation treated with amiodarone.
    McGovern B; Garan H; Malacoff RF; DiMarco JP; Grant G; Sellers TD; Ruskin JN
    Am J Cardiol; 1984 Jun; 53(11):1558-63. PubMed ID: 6731300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Out-of-hospital cardiac arrest in patients with no overt heart disease: electrophysiologic observations and clinical outcome.
    Bhandari AK; Hong R; Au P; McKay CR; Rahimtoola SH
    Can J Cardiol; 1988 Mar; 4(2):80-4. PubMed ID: 3365601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
    Baquero GA; Banchs JE; Depalma S; Young SK; Penny-Peterson ED; Samii SM; Wolbrette DL; Naccarelli GV; Gonzalez MD
    J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Electrical storm in idiopathic ventricular fibrillation is associated with early repolarization.
    Aizawa Y; Chinushi M; Hasegawa K; Naiki N; Horie M; Kaneko Y; Kurabayashi M; Ito S; Imaizumi T; Aizawa Y; Takatsuki S; Joo K; Sato M; Ebe K; Hosaka Y; Haissaguerre M; Fukuda K
    J Am Coll Cardiol; 2013 Sep; 62(11):1015-9. PubMed ID: 23747791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective evaluation of a discriminant function for prediction of recurrent symptomatic ventricular tachycardia or ventricular fibrillation in coronary artery disease patients receiving amiodarone and having inducible ventricular tachycardia at electrophysiologic study.
    Klein LS; Fineberg N; Heger JJ; Miles WM; Kammerling JM; Chang MS; Zipes DP; Prystowsky EN
    Am J Cardiol; 1988 May; 61(13):1024-30. PubMed ID: 3364357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment.
    Kühlkamp V; Mewis C; Mermi J; Bosch RF; Seipel L
    J Am Coll Cardiol; 1999 Jan; 33(1):46-52. PubMed ID: 9935007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Excellent long-term reproducibility of the electrophysiologic efficacy of quinidine in patients with idiopathic ventricular fibrillation and Brugada syndrome.
    Belhassen B; Glick A; Viskin S
    Pacing Clin Electrophysiol; 2009 Mar; 32(3):294-301. PubMed ID: 19272057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of recurrent ventricular fibrillation associated with inferolateral early repolarization role of drug therapy.
    Haïssaguerre M; Sacher F; Nogami A; Komiya N; Bernard A; Probst V; Yli-Mayry S; Defaye P; Aizawa Y; Frank R; Mantovan R; Cappato R; Wolpert C; Leenhardt A; de Roy L; Heidbuchel H; Deisenhofer I; Arentz T; Pasquié JL; Weerasooriya R; Hocini M; Jais P; Derval N; Bordachar P; Clémenty J
    J Am Coll Cardiol; 2009 Feb; 53(7):612-619. PubMed ID: 19215837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Programmed ventricular stimulation in predicting vulnerability to ventricular arrhythmias and their response to antiarrhythmic therapy.
    Mason JW; Swerdlow CD; Winkle RA; Griffin JC; Ross DL; Keefe DL; Clusin WT
    Am Heart J; 1982 Apr; 103(4 Pt 2):633-9. PubMed ID: 7064805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infarct related artery patency: relation to serial electropharmacological studies and outcome in patients with previous myocardial infarction and ventricular tachyarrhythmias.
    Hoppe UC; Haverkamp W; Breithardt G; Borggrefe M
    Pacing Clin Electrophysiol; 2000 May; 23(5):854-62. PubMed ID: 10833706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of programmed ventricular stimulation in patients with idiopathic dilated cardiomyopathy and documented sustained ventricular tachyarrhythmias: inducibility and prognostic value in 102 patients.
    Chen X; Shenasa M; Borggrefe M; Block M; Hindricks G; Martinez-Rubio A; Haverkamp W; Willems S; Böcker D; Mäkijärvi M
    Eur Heart J; 1994 Jan; 15(1):76-82. PubMed ID: 8174587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of ventricular fibrillation-flutter induced by ventricular programmed stimulation.
    DiCarlo LA; Morady F; Schwartz AB; Shen EN; Baerman JM; Krol RB; Scheinman MM; Sung RJ
    Am Heart J; 1985 May; 109(5 Pt 1):959-63. PubMed ID: 3993530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiarrhythmic effects of selective prolongation of refractoriness. Electrophysiologic actions of sematilide HCl in humans.
    Sager PT; Nademanee K; Antimisiaris M; Pacifico A; Pruitt C; Godfrey R; Singh BN
    Circulation; 1993 Sep; 88(3):1072-82. PubMed ID: 8353869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.